AQR Capital Management LLC Sells 19,600 Shares of OPKO Health, Inc. (NASDAQ:OPK)

AQR Capital Management LLC lowered its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 19.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,839 shares of the biotechnology company’s stock after selling 19,600 shares during the quarter. AQR Capital Management LLC’s holdings in OPKO Health were worth $100,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health in the second quarter valued at $592,000. Rubric Capital Management LP raised its stake in shares of OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the period. Hollencrest Capital Management raised its stake in shares of OPKO Health by 14.0% in the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the period. Y.D. More Investments Ltd purchased a new stake in shares of OPKO Health in the second quarter valued at $1,840,000. Finally, American Century Companies Inc. purchased a new stake in shares of OPKO Health in the second quarter valued at $112,000. Institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $34.49, for a total transaction of $1,724,500.00. Following the transaction, the insider now owns 2,646,972 shares of the company’s stock, valued at approximately $91,294,064.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 586,444 shares of company stock valued at $19,494,627. Company insiders own 47.26% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on OPK. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, September 20th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th.

OPKO Health Trading Up 0.7 %

OPK stock opened at $1.47 on Friday. The company has a market capitalization of $1.02 billion, a PE ratio of -4.19 and a beta of 1.63. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The firm’s 50-day moving average is $1.55 and its 200 day moving average is $1.40. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The business had revenue of $182.20 million for the quarter, compared to the consensus estimate of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The company’s revenue for the quarter was down 31.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. On average, research analysts anticipate that OPKO Health, Inc. will post -0.29 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.